In a welcome move, Tandem Diabetes Care saw its Relative Strength Rating rise from 61 to 73 on Thursday.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they launch their largest price moves. See if Tandem Diabetes Care can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Tandem Diabetes Care is now considered extended and out of buy range after clearing a 31.07 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company reported 0% EPS growth in its most recent report. Revenue rose 31%. Look for the next report on or around Feb. 26.
Tandem Diabetes Care holds the No. 61 rank among its peers in the Medical-Products industry group. Boston Scientific, Globus Medical and Insulet are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
